Literature DB >> 22820247

Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors.

Adam B Shapiro1, Beth Andrews.   

Abstract

A novel class of bacterial DNA gyrase inhibitors has been shown previously to form a ternary complex with DNA and gyrase in a site distinct from the fluoroquinolone and ATP binding sites and does not cause double-strand-cleaved complex stabilization like fluoroquinolones. We show that, unlike fluoroquinolones, a representative compound inhibits DNA-dependent ATP hydrolysis by Escherichia coli gyrase and also blocks cleaved complex stabilization by ciprofloxacin. Conversely, ciprofloxacin blocks ATPase inhibition by the novel compound. We conclude that the compound acts allosterically to inhibit ATP binding or hydrolysis and interferes with the gyrase catalytic cycle at a different point than ciprofloxacin.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820247     DOI: 10.1016/j.bcp.2012.07.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Authors:  Thomas J Dougherty; Asha Nayar; Joseph V Newman; Sussie Hopkins; Gregory G Stone; Michele Johnstone; Adam B Shapiro; Mark Cronin; Folkert Reck; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Authors:  Asha S Nayar; Thomas J Dougherty; Folkert Reck; Jason Thresher; Ning Gao; Adam B Shapiro; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

4.  Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Authors:  Katherine A Hurley; Thiago M A Santos; Molly R Fensterwald; Madhusudan Rajendran; Jared T Moore; Edward I Balmond; Brice J Blahnik; Katherine C Faulkner; Marie H Foss; Victoria A Heinrich; Matthew G Lammers; Lucas C Moore; Gregory D Reynolds; Galen P Shearn-Nance; Brian A Stearns; Zi W Yao; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

5.  The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors:  Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

6.  Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.

Authors:  Adam B Shapiro; Joseph Newman; Kosalaram Goteti; Marie-Eve Beaudoin; Rane Harrison; Sussie Hopkins; Nikunj Agrawal; Olga Rivin
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

7.  Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology.

Authors:  Manohary Rajendram; Katherine A Hurley; Marie H Foss; Kelsey M Thornton; Jared T Moore; Jared T Shaw; Douglas B Weibel
Journal:  ACS Chem Biol       Date:  2014-04-22       Impact factor: 5.100

Review 8.  Towards Conformation-Sensitive Inhibition of Gyrase: Implications of Mechanistic Insight for the Identification and Improvement of Inhibitors.

Authors:  Dagmar Klostermeier
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.